𝔖 Bobbio Scriptorium
✦   LIBER   ✦

243 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors

✍ Scribed by Bahleda, R.; Zimmer, L.; Garcia, M. Martinez; Dieras, V.


Book ID
123145781
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
59 KB
Volume
48
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.